{"id":34712,"date":"2025-06-30T09:30:40","date_gmt":"2025-06-30T13:30:40","guid":{"rendered":"https:\/\/advisory.avalerehealth.com\/?p=34712"},"modified":"2025-06-30T11:58:40","modified_gmt":"2025-06-30T15:58:40","slug":"a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting","title":{"rendered":"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting"},"content":{"rendered":"

On June 25-26, the newly reconstituted \u00a0Advisory Committee on Immunization Practices<\/a> (ACIP) held its first public meeting. The meeting offered insight into future directions for both the committee and the immunization programs that are guided by the committee\u2019s recommendations.<\/p>\n

Background<\/strong><\/p>\n

ACIP is a chartered federal advisory committee responsible for making recommendations on the safe and effective use of vaccines. The Committee makes these recommendations to the Centers for Disease Control and Prevention (CDC), and if adopted by the CDC Director and published in the respective Immunization Schedule, these recommendations enable Americans to access vaccines at no cost across most insurance programs.<\/p>\n

The ACIP is formally chartered under the Federal Advisory Committee Act (FACA, 1972), which ensures that federal advisory committees operate with open and transparent procedures, maintain public records of proceedings and recommendations to facilitate transparency and objectivity, and hold regular and publicly announced meetings. The committee meets at least three times per year, in February, June, and October. Three weeks in advance of the scheduled June meeting, Secretary of Health and Human Services Robert F. Kennedy Jr announced<\/a> \u00a0that he would remove all 17 sitting members of the committee, noting that 13 members were appointed in 2024 under the Biden administration and \u201ca clean sweep [was] necessary to reestablish public confidence in vaccine science.\u201d Two days later, Sec. Kennedy announced the names of eight new voting members<\/a> on the social media platform, X (formerly Twitter), one of whom withdrew<\/a> before the start of the June meeting, citing a review of his financial holdings and leaving the committee with seven sitting members.<\/p>\n

ACIP Is the Bedrock of the US Vaccine Policy and Access System<\/strong><\/p>\n

In the sixty years since its establishment, the ACIP has emerged as the cornerstone of US vaccine policy and access systems. Using a rigorous review process that assesses vaccine product safety, efficacy, cost-effectiveness, and programmatic fit, ACIP issues evidence-based recommendations on immunization use, and its recommendations form the foundation for pediatric and adult immunization schedules. These schedules not only guide clinical practice but also trigger first-dollar coverage across most insurance programs.<\/p>\n

Federal legislation has incrementally grown to require first-dollar coverage of ACIP-recommended vaccines for more insurance groups (Figure 1). This began with the Omnibus Budget Reconciliation Act in 1993<\/a>, which tied inclusion in the Vaccines for Children Program to an ACIP resolution. In 2010, the Affordable Care Act <\/a>requires commercial payers to cover all immunizations that have \u201cin effect a recommendation\u201d from the ACIP and further requires Medicaid expansion programs to cover ACIP-recommended products. These two pieces of legislation tied first-dollar coverage of vaccines for over two-thirds of the American population to ACIP recommendations. The remaining gaps in patient cost-sharing requirements were closed in 2022 with the passage of the Inflation Reduction Act<\/a>, which eliminated all cost sharing for adult vaccines recommended by ACIP under Medicare Part D, and mandated that traditional Medicaid and CHIP plans cover all approved vaccines recommended by ACIP along with their administration without cost sharing. For more detailed information on US vaccine coverage requirements, see Avalere\u2019s guidebook here<\/a>.<\/p>\n

Figure 1: Evolution of Immunization Coverage Requirements<\/strong><\/p>\n

\"\"RSV: Respiratory Syncytial Virus: VFC: Vaccines for Children<\/span><\/p>\n

In addition to the direct impact ACIP recommendations have on insurance coverage and patient access, the Committee\u2019s decisions also have an indirect impact on state immunization policies, provider counseling behavior, and quality reporting programs (see Figure 2).<\/p>\n

State public health departments often rely on ACIP recommendations to drive public health outreach campaigns as well as to shape school and occupational vaccination requirements. ACIP guidance is further embedded in state immunization information systems, which track vaccine administration, and may also be configured for integration with provider electronic health records using the CDC\u2019s clinical decision support for immunization tools.<\/p>\n

ACIP recommendations also impact provider scope of practice and quality measurement. State legislators or boards of pharmacy often adapt local pharmacist and pharmacy technician authority to administer vaccination to reflect ACIP recommendations. Quality reporting programs (e.g., childhood immunization status and adult immunization status measures) incorporate adherence to ACIP schedules as performance indicators for providers and health plans.<\/p>\n

In essence, ACIP recommendations shape which products are offered in US immunization programs, which patient populations can receive them at no cost, and how immunizations are tracked to assess risk of vaccine-preventable disease outbreaks.<\/p>\n

Figure 2: Direct and Indirect Impacts of ACIP Recommendations<\/strong><\/p>\n

\"\"<\/span><\/p>\n

VICP: Vaccine Injury Compensation Program<\/span><\/p>\n

The Committee Is Poised to Revisit the Pediatric Immunization Schedule <\/strong><\/p>\n

In addition to the seven new voting members who were introduced at this week\u2019s meeting, there was also an announcement of two new ACIP work groups, which will add to the extant product-specific work groups and the traditional work group focused on reviewing and updating the child\/adolescent and adult immunization schedules on an annual basis.<\/p>\n

The first new work group will examine the cumulative effect of the childhood vaccine schedule. The second new work group will review products which have not been subject to review in more than seven years \u2013 an extant requirement per ACIP Policies and Procedures<\/a><\/em> which has not been consistently observed. Combined, these work groups signal the reformulated committee\u2019s intention to review previously-established schedules and potentially revise them following new evaluations.<\/p>\n

The June meeting<\/a> initiated this process with discussions on the use of thimerosal-containing influenza vaccines and the use of the measles, mumps, rubella, and varicella (MMRV) vaccine in children. After a presentation on the risks associated with thimerosal the committee voted five-to-one (one abstention) to eliminate the use of thimerosal-containing influenza vaccines. This discussion diverged from the ACIP\u2019s traditional process, which has historically been guided by a structured review of the evidence across several clinical and programmatic domains using a framework called the \u2018Evidence to Recommendation\u2019 (EtR) framework.<\/p>\n

Following the thimerosal discussion, the new chair, Dr. Martin Kulldorff, presented on the risk of febrile seizures associated with the MMRV vaccine and introduced recommendation language to eliminate MMRV as an option for vaccination in children under 47 months of age. This recommendation will be voted on at a subsequent meeting. It is unclear whether a dedicated WG will be established to support this review or whether it will fall under the remit of one of the newly established work groups.<\/p>\n

Neither vote will significantly impact current immunization practices given the low utilization of both thimerosal-containing influenza vaccines and MMRV vaccines in children under four years of age. Still, these discussions may foreshadow additional re-evaluation of other recommendations, likely beginning with the pediatric immunization schedule which has been a major focus area for CDC and HHS leadership.<\/p>\n

Real-world Impacts of New or Revised Recommendations Remain Uncertain<\/strong><\/p>\n

ACIP recommendations typically fall into one of three categories: routine recommendations, which are recommended for standard use in a broad population; risk-based recommendations, which are tailored for specific populations that may be at higher risk due to age, medical conditions, or occupation; and shared clinical decision making (SCDM) recommendations, which are designed for situations where a vaccine may benefit some but not all individuals in a given cohort. In the case of SCDM recommendations, the decision to vaccinate should be made jointly between the patient and the provider. All three recommendation types determine coverage requirements across insurance programs.<\/p>\n

For patient populations no longer included in the scope of a given ACIP recommendation, payers may continue to voluntarily provide coverage and would be free to apply utilization management requirements\u2014apractice that is not permitted for ACIP-recommended immunizations. For patient populations that are not covered by the scope of an ACIP recommendation, payers may rely on internal product review committees to determine coverage or they may turn to relevant medical societies to inform their coverage protocols. Additionally, while ACIP recommendations establish the minimum coverage requirement for state Medicaid programs, they are free to offer broader coverage. \u00a0As payer coverage policies evolve, vaccine access may vary across geographies, patient populations, and insurance programs. .<\/p>\n

Conclusion<\/strong><\/p>\n

The current climate surrounding the ACIP is marked by considerable uncertainty, and further developments are likely to occur ahead of the next meeting in the fall. Further agency changes, such as the appointment and Senate confirmation of a CDC Director, could also shift the activities and objectives of the ACIP and the CDC staff who support the ACIP\u2019s research efforts.<\/p>\n

Further, given early withdrawals in participation from newly nominated members, additional membership could be solicited and approved in advance of other 2025 meetings. \u00a0Additionally, several recommendations from the April meeting remain unadopted and recommendations for other seasonally administered vaccines, like COVID-19, have not yet been voted on, raising questions about whether those recommendations may be revisited in future meetings. In the interim, payers, providers, and industry stakeholders will be monitoring the situation closely for any shifts in evidentiary standards or substantive revisions of existing recommendations.<\/p>\n","protected":false},"excerpt":{"rendered":"

On June 25-26, the newly reconstituted \u00a0Advisory Committee on Immunization Practices (ACIP) held its first public meeting. The meeting offered insight into future directions for both the committee and the immunization programs that are guided by the committee\u2019s recommendations. Background ACIP is a chartered federal advisory committee responsible for making recommendations on the safe and…<\/p>\n","protected":false},"author":28,"featured_media":21995,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"content-categories":[131],"class_list":["post-34712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights","content-categories-vaccines","entry","has-media"],"acf":[],"yoast_head":"\nA Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting | Avalere Health Advisory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting | Avalere Health Advisory\" \/>\n<meta property=\"og:description\" content=\"On June 25-26, the newly reconstituted \u00a0Advisory Committee on Immunization Practices (ACIP) held its first public meeting. The meeting offered insight into future directions for both the committee and the immunization programs that are guided by the committee\u2019s recommendations. Background ACIP is a chartered federal advisory committee responsible for making recommendations on the safe and…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting\" \/>\n<meta property=\"og:site_name\" content=\"Avalere Health Advisory\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-30T13:30:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-30T15:58:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/20790-1-Sarah_Moselle400x600.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leah Keller\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:site\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leah Keller\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting | Avalere Health Advisory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting","og_locale":"en_US","og_type":"article","og_title":"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting | Avalere Health Advisory","og_description":"On June 25-26, the newly reconstituted \u00a0Advisory Committee on Immunization Practices (ACIP) held its first public meeting. The meeting offered insight into future directions for both the committee and the immunization programs that are guided by the committee\u2019s recommendations. Background ACIP is a chartered federal advisory committee responsible for making recommendations on the safe and…","og_url":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting","og_site_name":"Avalere Health Advisory","article_published_time":"2025-06-30T13:30:40+00:00","article_modified_time":"2025-06-30T15:58:40+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/20790-1-Sarah_Moselle400x600.jpg","type":"image\/jpeg"}],"author":"Leah Keller","twitter_card":"summary_large_image","twitter_creator":"@avalerehealth","twitter_site":"@avalerehealth","twitter_misc":{"Written by":"Leah Keller","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#article","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting"},"author":{"name":"Leah Keller","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/fb195190cdd6a0c7c2cc890515dd95f4"},"headline":"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting","datePublished":"2025-06-30T13:30:40+00:00","dateModified":"2025-06-30T15:58:40+00:00","mainEntityOfPage":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting"},"wordCount":1458,"commentCount":0,"publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#primaryimage"},"thumbnailUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/20790-1-Sarah_Moselle400x600.jpg","articleSection":["Insights & Analysis"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#respond"]}]},{"@type":"WebPage","@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting","url":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting","name":"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting | Avalere Health Advisory","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#primaryimage"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#primaryimage"},"thumbnailUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/20790-1-Sarah_Moselle400x600.jpg","datePublished":"2025-06-30T13:30:40+00:00","dateModified":"2025-06-30T15:58:40+00:00","breadcrumb":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#primaryimage","url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/20790-1-Sarah_Moselle400x600.jpg","contentUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/02\/20790-1-Sarah_Moselle400x600.jpg","width":600,"height":400,"caption":"Sarah Moselle"},{"@type":"BreadcrumbList","@id":"https:\/\/advisory.avalerehealth.com\/insights\/a-turning-point-for-us-vaccine-policy-signals-from-the-june-acip-meeting#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/advisory.avalerehealth.com\/"},{"@type":"ListItem","position":2,"name":"A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting"}]},{"@type":"WebSite","@id":"https:\/\/advisory.avalerehealth.com\/#website","url":"https:\/\/advisory.avalerehealth.com\/","name":"Avalere Health Advisory","description":"","publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/advisory.avalerehealth.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/advisory.avalerehealth.com\/#organization","name":"Avalere Health","url":"https:\/\/advisory.avalerehealth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/","url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","contentUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","width":433,"height":47,"caption":"Avalere Health"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/avalerehealth"]},{"@type":"Person","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/fb195190cdd6a0c7c2cc890515dd95f4","name":"Leah Keller","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4a87f9cf63da84fab5720429686278df?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a87f9cf63da84fab5720429686278df?s=96&d=mm&r=g","caption":"Leah Keller"},"description":"Leah Keller co-manages and edits the Policy 360 Research Series sits on Avalere\u2019s Marketing Team. Prior to joining Avalere, Leah conducted policy research and analysis on federal healthcare issues such as Medicaid coverage and payment, commercial insurance coverage and access, healthcare reform, and ACA implementation at the Guttmacher Institute, a thinktank focused on advancing reproductive health and rights. Prior, Leah coordinated data collection, analysis, and publications for George Washington University\u2019s Center for Social Well-Being and Development. Leah holds an MPH in maternal and child health from George Washington University and a BA in anthropology from St. Mary\u2019s College of Maryland.","url":"https:\/\/advisory.avalerehealth.com\/author\/lkelleravalere-com"}]}},"_links":{"self":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/34712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/comments?post=34712"}],"version-history":[{"count":2,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/34712\/revisions"}],"predecessor-version":[{"id":34716,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/34712\/revisions\/34716"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/media\/21995"}],"wp:attachment":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/media?parent=34712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/categories?post=34712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/tags?post=34712"},{"taxonomy":"content-categories","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/content-categories?post=34712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}